RNA-targeted small molecules are rapidly emerging as one of the most exciting areas in drug discovery, with growing clinical validation demonstrating the potential to address historically undruggable ...

GSK has continued its drive to bulk up its pipeline, taking global rights to a T-cell engager (TCE) for multiple myeloma, ...

The planned IPO comes after Electra raised $183 million in a Series C that completed last October, as it started dosing ...

Khougazian – who is currently at investment group Flagship Pioneering – will take over as CEO of Chiesi on 15th October, ...

The organisation should not automatically double simply because revenue does. These are directional ranges, not rules, but they expose an important principle: headcount growth should normally lag ...

On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...

BioNTech and partner OncoC4's anti-CTLA-4 immunotherapy gotistobart almost doubled survival in a trial involving patients with a hard-to-treat form of lung cancer, ahead of a pivotal readout due next ...

The Danish Group stated that the new corporate culture – dubbed 'The Novo Way' – centres around four Cs; namely, customer ...

The offer is legally conditioned upon the private equity company's Respighi BidCo vehicle securing at least a two-thirds ...

There's been a lot of talk about forging closer ties between Europe and Canada in response to the US' aggressive disruption of international trade. Now, two senior figures in Canada's life sciences ...

HHS has moved to firm up the leadership at the FDA after a long period of uncertainty and disruption, upgrading the heads of the agency's centres governing drugs and biologics from acting to permanent ...

Etcamah is already approved in the US, Europe, and other markets for use in combination with a CDK4/6 inhibitor as a ...